Latest Breaking News On - Lancet respir med - Page 1 : vimarsana.com

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

Phanes Therapeutics Announces the Appointment of Internationally Renowned Oncologist Prof. Shun Lu to its Clinical Advisory Board

/PRNewswire/ Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, today.

Correction to Lancet Respir Med 2023; published online Jan 23. https://doi.org/10.1016/S2213-2600(22)00530-6

Beasley R, Chang AB. Is tezepelumab the ubiquitous biologic for severe asthma? Lancet Respir Med 2023; published online Jan 23. https://doi.org/10.1016/S2213-2600(22)00530-6 In this Comment, the last sentence of the sixth paragraph should read “Therefore, patients should receive a trial of the simple and relatively inexpensive ICS–formoterol maintenance and reliever therapy before initiation of biologic therapies.” This correction has been made to the online version as of Feb 3, 2023, and will be made to the printed version.

Correction to Lancet Respir Med 2022; published online April 11. https://doi.org/10.1016/S2213-2600(22)00059-5

LivaNova PLC: LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea

Study to evaluate effectiveness of hypoglossal nerve stimulation LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced the first patient implanted

Lenzilumab improves survival without ventilation in patients hospitalized with COVID-19

Correction to Lancet Respir Med 2021; 9: 340–42

Colchicine treatment in COVID-19: the remaining unsolved question

Frontiers | Complication and Sequelae of COVID-19: What Should We Pay Attention to in the Post-Epidemic Era

Frontiers | Systems Immunology Analysis Reveals the Contribution of Pulmonary and Extrapulmonary Tissues to the Immunopathogenesis of Severe COVID-19 Patients

2Luebeck Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany 3General Surgery Department, Tawam Hospital, SEHA, Al Ain, United Arab Emirates 4Center for Biotechnology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 5Department of Genetics and Molecular Biology, Khalifa University of Science and Technology, Abu Dhabi, United Arab Emirates 6Department of Respiratory Medicine, Rashid Hospital, Dubai Health Authority, Dubai, United Arab Emirates 7Meakins-Christie Laboratories, McGill University, Montreal, QC, Canada 8Division of Surgery and Interventional Science, University College London, London, United Kingdom As one of the current global health conundrums, COVID-19 pandemic caused a dramatic increase of cases exceeding 79 million and 1.7 million deaths worldwide. Severe presentation of COVID-19 is characterized by cytokine storm and chronic inflammation resulting in multi-organ dysfunction. Currently, it is unclear whet